russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2021-4798russjcardiol-4798Research ArticleПРЕСС-РЕЛИЗПациент высокого сердечно-сосудистого риска – фокус на результат. Коррекция дислипидемий в клинической практике кардиолога, педиатра, невролога и эндокринологаHigh cardiovascular risk patient — focus on results. Treatment of dyslipidemia in the clinical practice of a cardiologist, pediatrician, neurologist and endocrinologistРедакционнаяСтатьяEditorialArticle202103122021261247984798Copyright © Редакционная С., 20222022Редакционная С.Editorial A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/4798

23 октября 2021г в Санкт-Петербурге в рамках Российского национального конгресса кардиологов прошел Международный мультидисциплинарный форум, посвященный современным стратегиям управления сердечно-сосудистыми рисками. В насыщенной программе форума были доклады экспертов разных специальностей из России, Израиля, Нидерландов, Греции. Все сообщения объединяла одна актуальная проблема: оптимизация стратегии коррекции липидного профиля на основе оценки рисков.

.

Форум и подготовка материалов статьи состоялись при поддержке компании АмдженThe forum and the preparation of article materials were supported by the Amgen companyReferences2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Dyslipidaemias-Management-of.2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Dyslipidaemias-Management-of.Varenhorst C, Hasvold P, Johansson S, et al. Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc. 2018;7(1):e007174. doi:10.1161/JAHA.117.007174.Varenhorst C, Hasvold P, Johansson S, et al. Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc. 2018;7(1):e007174. doi:10.1161/JAHA.117.007174.Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-86. doi:10.1001/jama.297.2.177.Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-86. doi:10.1001/jama.297.2.177.Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012;344:d8059. doi:10.1136/bmj.d8059.Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012;344:d8059. doi:10.1136/bmj.d8059.Wiviott SD, Cannon CP, Morrow DA, et al.; PROVE IT-TIMI 22 Investigators. Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411-6. doi:10.1016/j.jacc.2005.04.064.Wiviott SD, Cannon CP, Morrow DA, et al.; PROVE IT-TIMI 22 Investigators. Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411-6. doi:10.1016/j.jacc.2005.04.064.Kotseva K, on behalf of EUROASPIRE investigators. Presented at ESC 2018, Munich. https://esc365.escardio.org/Congress/ESC-Congress-2018/Implementation-of-cardiovasculardisease-prevention-in-daily-practice-Insig/174542-reaching-lipid-targets-in-coronarypatents-temporal-trends-and-state-of-the-art#slide (10.09.2018).Kotseva K, on behalf of EUROASPIRE investigators. Presented at ESC 2018, Munich. https://esc365.escardio.org/Congress/ESC-Congress-2018/Implementation-of-cardiovasculardisease-prevention-in-daily-practice-Insig/174542-reaching-lipid-targets-in-coronarypatents-temporal-trends-and-state-of-the-art#slide (10.09.2018).Catapano AL, Graham I, Backer GD, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37:2999-3058. doi:10.1093/eurheartj/ehw272.Catapano AL, Graham I, Backer GD, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37:2999-3058. doi:10.1093/eurheartj/ehw272.Toth PP, Patti AM, Giglio RV, et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs. 2018;18(3):157-73. doi:10.1007/s40256-017-0259-7.Toth PP, Patti AM, Giglio RV, et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs. 2018;18(3):157-73. doi:10.1007/s40256-017-0259-7.Национальное общество по изучению атеросклероза (НОА), Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР). Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза Российские рекомендации. VI пересмотр. Москва, 2017. http://noatero.ru/ru/diagnostika-ikorrekciya-narusheniy-lipidnogo-obmena-s-celyu-profilaktiki-i-lecheniya-ateroskleroza.National Society for the Study of Atherosclerosis (NOA), Russian Society for Cardiosomatic Rehabilitation and Secondary Prevention (ROSOKR). Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis Russian recommendations. VI revision. Moscow, 2017. (In Russ.) http://noatero.ru/ru/diagnostika-ikorrekciya-narusheniy-lipidnogo-obmena-s-celyu-profilaktiki-i-lecheniya-ateroskleroza.Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664.Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664.Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452-62. doi:10.1016/j.jacc.2019.08.010.Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452-62. doi:10.1016/j.jacc.2019.08.010.Leucker TM, Blaha MJ, Jones SR, et al. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial. Circulation. 2020;142(4):419-21. doi:10.1161/CIRCULATIONAHA.120.046320.Leucker TM, Blaha MJ, Jones SR, et al. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial. Circulation. 2020;142(4):419-21. doi:10.1161/CIRCULATIONAHA.120.046320.Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. doi:10.1016/S0140-6736(05)67394-1.Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. doi:10.1016/S0140-6736(05)67394-1.Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-84. doi:10.1001/jama.2016.16951.Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-84. doi:10.1001/jama.2016.16951.Colantonio LD, Hubbard D, Monda KL. Atherosclerotic Risk and Statin Use Among Pa - tients With Peripheral Artery Disease. J Am Coll Cardiol. 2020;76(3):251-64. doi:10.1016/j.jacc.2020.05.048.Colantonio LD, Hubbard D, Monda KL. Atherosclerotic Risk and Statin Use Among Pa - tients With Peripheral Artery Disease. J Am Coll Cardiol. 2020;76(3):251-64. doi:10.1016/j.jacc.2020.05.048.Ray KK, Laufs U, Cosentino F, et al. The year in cardiology: cardiovascular prevention. Eur Heart J. 2020;41(11):1157-63. doi:10.1093/eurheartj/ehz929.Ray KK, Laufs U, Cosentino F, et al. The year in cardiology: cardiovascular prevention. Eur Heart J. 2020;41(11):1157-63. doi:10.1093/eurheartj/ehz929.Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. doi:10.1161/CIRCULATIONAHA.117.032235.Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. doi:10.1161/CIRCULATIONAHA.117.032235.Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322(14):1381-91. doi:10.1001/jama.2019.14120.Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019;322(14):1381-91. doi:10.1001/jama.2019.14120.Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484.Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002.Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-42. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.Nordestgaard BG, Chapman MJ, Humphries SE, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. doi:10.1093/eurheartj/eht273.Nordestgaard BG, Chapman MJ, Humphries SE, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. doi:10.1093/eurheartj/eht273.Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2021:ehab718. doi:10.1093/eurheartj/ehab718.Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2021:ehab718. doi:10.1093/eurheartj/ehab718.Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020;5(2):217-29. doi:10.1001/jamacardio.2019.5173.Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020;5(2):217-29. doi:10.1001/jamacardio.2019.5173.Концевая А.В., Драпкина О.М., Баланова Ю.A. и др. Экономический ущерб сердечно-сосудистых заболеваний в Российской Федерации в 2016 году. Рациональная фармакотерапия в кардиологии. 2018;14(2):156-16. doi:10.20996/1819-6446-2018-14-2-156-166.Kontsevaya AV, Drapkina OM, Balanova YuA, et al. Economic damage of cardiovascular diseases in the Russian Federation in 2016. Rational pharmacotherapy in cardiology. 2018;14(2):156-16. (In Russ.) doi:10.20996/1819-6446-2018-14-2-156-166.Коновалов Г.А., Бажан С.С. Эволокумаб: инновационные возможности снижения холестерина липопротеидов низкой плотности, липопротеида (а) и управления сердечно-сосудистым риском. Кардиология: новости, мнения, обучение. 2017;2:45-56. doi:10.24411/2309-1908-2017-00025.Konovalov GA, Bazhan SS. Evolokumab: innovative possibilities of lowering low-density lipoprotein cholesterol, lipoprotein (a) and cardiovascular risk management. Cardiology: news, opinions, training. 2017;2:45-56. (In Russ.) doi:10.24411/2309-1908-2017-00025.Itzhaki Ben Zadok O, Mager A, Leshem-Lev D, et al. The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-020-07119-1.Itzhaki Ben Zadok O, Mager A, Leshem-Lev D, et al. The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-020-07119-1.Wiegman A, Gidding SS, Watts GF, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37. doi:10.1093/eurheartj/ehv157.Wiegman A, Gidding SS, Watts GF, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37. doi:10.1093/eurheartj/ehv157.Macchiaiolo M, Gagliardi MG, Toscano A, et al. Homozygous familial hypercholesterolaemia. Lancet. 2012;379(9823):1330. doi:10.1016/S0140-6736(11)61476-1.Macchiaiolo M, Gagliardi MG, Toscano A, et al. Homozygous familial hypercholesterolaemia. Lancet. 2012;379(9823):1330. doi:10.1016/S0140-6736(11)61476-1.Widhalm K, Binder CB, Kreissl A, et al. Sudden death in a 4-year-old boy: a nearcomplete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr. 2011;158(1):167. doi:10.1016/j.jpeds.2010.06.027.Widhalm K, Binder CB, Kreissl A, et al. Sudden death in a 4-year-old boy: a nearcomplete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr. 2011;158(1):167. doi:10.1016/j.jpeds.2010.06.027.Wiegman A, et al. Unpublished data Feb 2021.Wiegman A, et al. Unpublished data Feb 2021.de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109(23 Suppl 1): III33-8. doi:10.1161/01.CIR.0000131516.65699.ba.de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109(23 Suppl 1): III33-8. doi:10.1161/01.CIR.0000131516.65699.ba.Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-56. doi:10.1056/NEJMoa1816454.Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-56. doi:10.1056/NEJMoa1816454.Santos RD, Ruzza A, Hovingh GK, et al.; HAUSER-RCT Investigators. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14): 1317-27. doi:10.1056/NEJMoa2019910.Santos RD, Ruzza A, Hovingh GK, et al.; HAUSER-RCT Investigators. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14): 1317-27. doi:10.1056/NEJMoa2019910.Repatha. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/repatha-0.Repatha. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/repatha-0.FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-ages10-rare-forms-high-cholesterol.FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-ages10-rare-forms-high-cholesterol.Mohan KM, Wolfe CD, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489-94. doi:10.1161/STROKEAHA.110.602615.Mohan KM, Wolfe CD, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489-94. doi:10.1161/STROKEAHA.110.602615.Bravata DM, Ho SY, Meehan TP, et al. Readmission and death after hospitalization for acute ischemic stroke: 5-year follow-up in the medicare population. Stroke. 2007;38(6):1899-904. doi:10.1161/STROKEAHA.106.481465.Bravata DM, Ho SY, Meehan TP, et al. Readmission and death after hospitalization for acute ischemic stroke: 5-year follow-up in the medicare population. Stroke. 2007;38(6):1899-904. doi:10.1161/STROKEAHA.106.481465.Milionis H, Ntaios G, Korompoki E, et al. Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. Int J Stroke. 2020;15(4):377-84. doi:10.1177/1747493019873594.Milionis H, Ntaios G, Korompoki E, et al. Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. Int J Stroke. 2020;15(4):377-84. doi:10.1177/1747493019873594.Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-63. doi:10.1016/S1474-4422(09)70058-4.Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-63. doi:10.1016/S1474-4422(09)70058-4.Shin J, Chung JW, Jang HS, et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol. 2019:2047487319830503. doi:10.1177/2047487319830503.Shin J, Chung JW, Jang HS, et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol. 2019:2047487319830503. doi:10.1177/2047487319830503.Amarenco P, Kim JS, Labreuche J, et al. Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020;382(1):9. doi:10.1056/NEJMoa1910355.Amarenco P, Kim JS, Labreuche J, et al. Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020;382(1):9. doi:10.1056/NEJMoa1910355.Sagris D, Ntaios G, Georgiopoulos G, et al. Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. Int J Stroke. 2021;16(6):738-50. doi:10.1177/1747493020971970.Sagris D, Ntaios G, Georgiopoulos G, et al. Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. Int J Stroke. 2021;16(6):738-50. doi:10.1177/1747493020971970.Вознюк И.А., Шамалов Н.А., Ежов М.В. и др. Оптимизация гиполипидемической терапии у пациентов, перенесших ишемический инсульт. Резолюция Совета экспертов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):152- 61. doi:10.17116/jnevro2020120061152.Voznyuk IA, Shamalov NA, Yezhov MV, et al. Optimization of lipid-lowering therapy in patients who have suffered an ischemic stroke. Resolution of the Council of Experts. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2020;120(6):152-61. (In Russ.) doi:10.17116/jnevro2020120061152.Saposnik G, Fonarow GC, Pan W, et al.; AHA Get-with-the-Guidelines Stroke. Guidelinedirected low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. Stroke. 2014;45(11):3343-51. doi:10.1161/STROKEAHA.114.006736.Saposnik G, Fonarow GC, Pan W, et al.; AHA Get-with-the-Guidelines Stroke. Guidelinedirected low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. Stroke. 2014;45(11):3343-51. doi:10.1161/STROKEAHA.114.006736.Eun MY, Jung JM, Choi KH, Seo WK. Statin Effects in Atrial Fibrillation-Related Stroke: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:589684. doi:10.3389/fneur.2020.589684.Eun MY, Jung JM, Choi KH, Seo WK. Statin Effects in Atrial Fibrillation-Related Stroke: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:589684. doi:10.3389/fneur.2020.589684.Всероссийское общество неврологов и др. Ишемический инсульт и транзиторная ишемическая атака у взрослых. Российские клинические рекомендации-2020. https://cr.minzdrav.gov.ru/recomend/171_2.All-Russian Society of Neurologists. Ischemic stroke and transient ischemic attack in adults. Russian clinical Guidelines-2020. (In Russ.) https://cr.minzdrav.gov.ru/recomend/171_2.

The authors declare that there are no conflicts of interest present.